CytoMed Therapeutics Limited (GDTC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chee Kong Choo | Executive Chairman | 27.32k | -- | 1958 |
| Dr. Wee Kiat Tan Ph.D. | Co-CEO, COO & Director | 88.13k | -- | 1987 |
| Dr. Jieming Zeng M.D., Ph.D. | Chief Scientific & Medical Officer and Director | 89.74k | -- | 1974 |
| Ms. Yvonne Goh | Chief Financial Officer | -- | -- | 1990 |
| Dr. Tien Wee Luk M.D. | Chief Clinical Officer | -- | -- | 1986 |
| Ms. Yoong Ying Tan | Chief Corporate Officer | -- | -- | 1989 |
CytoMed Therapeutics Limited
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available